Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.56 |
| ▸ | GABRD | O14764 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.56 |
| ▸ | GABRE | P78334 | 1/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589262 | 1.00 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrazine SCHEMBL4704048 | 0.97 | GABRP (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4475387 | 0.86 | NNMT (0.50) | MEN1KMT2ANPC1LMNAPKM | |
| SCHEMBL2371616 | 0.84 | NNMT (0.57) | MEN1KMT2ANPC1LMNAPKM | |
| SCHEMBL31353398 | 0.84 | ALDH1A1 (0.51) | MEN1KMT2ANPC1LMNAPKM | |
| SCHEMBL30195950 | 0.84 | NPC1 (0.51) | MEN1KMT2ANPC1LMNAPKM | |
| SCHEMBL5881889 | 0.84 | MAPT (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2492499 | 0.84 | NPC1 (0.51) | MEN1KMT2ANPC1LMNAPKM | |
| SCHEMBL29590839 | 0.84 | NNMT (0.57) | MEN1KMT2ANPC1LMNAPKM | |
| SCHEMBL6069860 | 0.83 | P4HTM (0.58) | P4HTMMEN1KMT2ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20250188032-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | BNH RESEARCH CO., LTD. (KR) | 2025-06-12 | — | — | US | disclosed |
| EP-4501910-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | BNH Research Co., Ltd. (KR) | 2025-02-05 | — | — | EP | disclosed |
| EP-4426681-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2024-09-11 | — | — | EP | disclosed |
| CN-118317951-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| CN-114478519-B | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| WO-2023191468-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | 주식회사 비엔에이치리서치 | 2023-10-05 | — | — | WO | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| US-20060205741-A1 | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006078834-A1 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-27 | — | — | WO | disclosed |
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205741-A1 | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors | GPER1, ESR1, ESR2 | GABRP 943/4885GABRD 375/4885GABRA1 408/4885 |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | GABRP 3474/4885GABRD 3429/4885GABRA1 2918/4885 |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GABRP 722/4885GABRD 1651/4885GABRA1 311/4885 |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | RORB, RORC, RORA | GABRP 236/4885GABRD 214/4885GABRA1 50/4885 |
| US-20250188032-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | NLN, GRIN1, GRIN2A | GABRP 602/4885GABRD 761/4885GABRA1 284/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | GABRP 705/4885GABRD 1714/4885GABRA1 276/4885 |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | GABRP 1696/4885GABRD 4021/4885GABRA1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.